Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emad Daher

Internal Medicine Port Huron, MI Medical Doctor

NPI 1265415285 CMS profile 147556

1210 10Th Ave, Port Huron, MI 48060

Open in the dashboard

General payments

$10,355

615 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emad Daher of Port Huron, MI is reported in the CMS Open Payments database as having received $10,355 across 615 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,943 115
2024 General $1,900 99
2023 General $1,507 88
2022 General $1,575 90
2021 General $1,316 91
2020 General $904 51
2019 General $1,210 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emad Daher
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Emad Daher were reported at $1,943. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Emad Daher Internal Medicine median Middle half National median
2019 $1,210 $159 $48–$570 $163
2020 $904 $119 $33–$402 $114
2021 $1,316 $135 $37–$521 $132
2022 $1,575 $141 $42–$496 $149
2023 $1,507 $149 $45–$519 $160
2024 $1,900 $154 $47–$537 $164
2025 $1,943 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,349 93 payments
  2. Amgen Inc. $1,280 70 payments
  3. Pfizer Inc. $1,275 67 payments
  4. AstraZeneca Pharmaceuticals LP $999 55 payments
  5. Lilly USA, LLC $757 48 payments
  6. AbbVie, Inc. $597 52 payments
  7. Otsuka America Pharmaceutical, Inc. $440 18 payments
  8. Janssen Pharmaceuticals, Inc $411 29 payments
  9. Novartis Pharmaceuticals Corporation $309 18 payments
  10. Sanofi-Aventis U.S. LLC $265 9 payments
  11. Other $2,673 156 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,337 613 payments
  2. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $910 65 payments
  2. RYBELSUS $870 64 payments
  3. Repatha $781 37 payments
  4. FARXIGA $701 36 payments
  5. NURTEC ODT $619 32 payments
  6. ELIQUIS $601 31 payments
  7. MOUNJARO $497 28 payments
  8. Otezla $470 42 payments
  9. REXULTI $462 19 payments
  10. XARELTO $406 28 payments
  11. Other $8,545 523 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 261 drugs

Part D claims

27,098

Median for Internal Medicine: 777

Drug cost

$3,234,564

Median for Internal Medicine: $73,373

Branded share of claims

25.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 588 $480,529
Jardiance Empagliflozin Brand 360 $358,817
Eliquis Apixaban Brand 386 $333,783
Mounjaro Tirzepatide Brand 276 $290,541
Ozempic Semaglutide Brand 207 $271,458
Trulicity Dulaglutide Brand 116 $166,417
Xarelto Rivaroxaban Brand 130 $108,512
Rybelsus Semaglutide Brand 44 $81,259
Januvia Sitagliptin Phosphate Brand 72 $80,612
Myrbetriq Mirabegron Brand 67 $56,872

The 10 drugs with the highest cost, of 261 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$229,303

Of which drugs: $5,004

Medicare patients

496

Average age 76

Services billed

3,666

265 women, 231 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 53%
Diabetes 34%
Atrial fibrillation 28%
Depression 28%
Chronic kidney disease 27%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 62 62 $4,991
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 21 104 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $266
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $22
$288 — —
MOUNJARO
  • Lilly USA, LLC $200
$200 276 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $166
$166 588 —
Repatha
  • Amgen Inc. $156
$156 90 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $147
$147 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

615 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record